Workflow
创业板
icon
Search documents
重启五套标准,一级医药市场熬过至暗时刻?
Sou Hu Cai Jing· 2025-06-19 08:16
Core Viewpoint - The enthusiasm of investors in the pharmaceutical primary market has been reignited due to the China Securities Regulatory Commission's announcement of the "1+6" policy measures, which will support unprofitable innovative companies in listing on the Sci-Tech Innovation Board (STAR Market) [1][9]. Group 1: Policy Changes - The introduction of the "new fifth set" listing standards aims to provide a differentiated listing channel for innovative companies that are in the high R&D investment phase but have not yet achieved stable revenue [3][4]. - The "1" in the "1+6" policy refers to the establishment of a Sci-Tech Growth Layer on the STAR Market, which will include all existing and newly registered unprofitable technology companies [3]. - The fifth set of standards will expand its applicability beyond biomedicine to include sectors such as artificial intelligence, commercial aerospace, and low-altitude economy [7]. Group 2: Market Impact - The previous tightening of the STAR Market and the discounting of Hong Kong IPOs led to a significant reduction in investment activity in the pharmaceutical sector, but the reintroduction of the fifth set of standards is expected to enhance investment willingness and risk appetite in the primary market [1][2]. - Since the STAR Market's inception, 20 innovative biopharmaceutical companies have utilized the fifth set of standards for fundraising, with the total investment amount in the biopharmaceutical sector reaching a peak of $34 billion in 2021 [8]. - In 2022, the total investment in the domestic pharmaceutical industry dropped to $15.6 billion, halving compared to the previous year, and further decreased to $10.9 billion in 2023, marking a 30% year-on-year decline [8]. Group 3: Investor Sentiment - The new policies are expected to restore key listing channels for unprofitable pharmaceutical companies, thereby boosting investor confidence and attracting social capital into the biopharmaceutical sector [9]. - There are concerns about potential overheating in the market due to the execution of these policies and the resonance with market sentiment, which could lead to high valuations or share price declines for some unprofitable technology companies post-listing [9].
上证指数收报3362.11点,跌0.79%。深证成指收报10051.97点,跌1.21%。创业板指收报2026.82点,跌1.36%。沪深300收报3843.09点,跌0.82%。科创50收报962.94点,跌0.54%。中证500收报5676.83点,跌1.20%。中证1000收报6048.22点,跌1.42%。
news flash· 2025-06-19 07:09
上证指数收报3362.11点,跌0.79%。 深证成指收报10051.97点,跌1.21%。 创业板指收报2026.82点,跌1.36%。 沪深300收报3843.09点,跌0.82%。 科创50收报962.94点,跌0.54%。 中证500收报5676.83点,跌1.20%。 中证1000收报6048.22点,跌1.42%。 ...
中国上证综指6月19日(周四)收盘下跌26.7点,跌幅:0.79%,报3362.11点;中国深证成指6月19日(周四)收盘下跌123.62点,跌幅:1.21%,报10051.97点;中国沪深300指数6月19日(周四)收盘下跌31.88点,跌幅:0.82%,报3843.09点;中国创业板指数6月19日(周四)收盘下跌27.91点,跌幅:1.36%,报2026.82点;中国科创50指数6月19日(周四)收盘下跌5.24点,跌幅:0.54%,报962.94点。
news flash· 2025-06-19 07:07
中国上证综指6月19日(周四)收盘下跌26.7点,跌幅:0.79%,报3362.11点; 中国深证成指6月19日(周四)收盘下跌123.62点,跌幅:1.21%,报10051.97点; 中国沪深300指数6月19日(周四)收盘下跌31.88点,跌幅:0.82%,报3843.09点; 中国创业板指数6月19日(周四)收盘下跌27.91点,跌幅:1.36%,报2026.82点; 中国科创50指数6月19日(周四)收盘下跌5.24点,跌幅:0.54%,报962.94点。 ...
A股午后持续走低 三大股指均跌超1%
news flash· 2025-06-19 05:05
暗盘资金正涌入这些股票,点击速看>>> A股午后持续走低,三大股指均跌超1%,创业板指跌1.39%,深证成指跌1.25%,全市场超4700只个股 飘绿。 ...
中国上证综指6月19日(周四)开盘下跌4.52点,跌幅:0.13%,报3384.29点;中国深证成指6月19日(周四)开盘下跌19.41点,跌幅:0.19%,报10156.17点;中国沪深300指数6月19日(周四)开盘下跌4.92点,跌幅:0.13%,报3870.05点;中国创业板指数6月19日(周四)开盘下跌5.55点,跌幅:0.27%,报2049.18点;中国科创50指数6月19日(周四)开盘下跌1.26点,跌幅:0.13%,报966.92点。
news flash· 2025-06-19 01:30
中国上证综指6月19日(周四)开盘下跌4.52点,跌幅:0.13%,报3384.29点; 中国深证成指6月19日(周四)开盘下跌19.41点,跌幅:0.19%,报10156.17点; 中国沪深300指数6月19日(周四)开盘下跌4.92点,跌幅:0.13%,报3870.05点; 中国创业板指数6月19日(周四)开盘下跌5.55点,跌幅:0.27%,报2049.18点; 中国科创50指数6月19日(周四)开盘下跌1.26点,跌幅:0.13%,报966.92点。 ...
新恒汇: 上海市锦天城律师事务所关于公司首次公开发行股票并在创业板上市的法律意见书
Zheng Quan Zhi Xing· 2025-06-18 13:23
Core Viewpoint - The legal opinion issued by Shanghai Jintiancheng Law Firm confirms that Xinhenghui Electronics Co., Ltd. has met all necessary legal requirements for its initial public offering (IPO) and listing on the ChiNext board, including internal approvals and regulatory compliance [1][4][9]. Group 1: Approval and Authorization - The company held its annual general meeting on April 29, 2022, where it approved the proposal for the IPO, with the resolution valid for 12 months until April 28, 2023, and subsequently extended to April 28, 2026 [4][5]. - The Shenzhen Stock Exchange's Listing Review Committee approved the company's IPO application on March 22, 2023 [5]. - The China Securities Regulatory Commission (CSRC) granted approval for the IPO registration on March 18, 2025, valid for 12 months [5]. - The Shenzhen Stock Exchange issued a notice on June 18, 2025, allowing the company's shares to be listed on the ChiNext board under the stock code "301678" [5]. Group 2: Company Qualifications - The company holds a valid business license issued by the Zibo Administrative Approval Service Bureau, confirming its legal existence and operational status [6]. - Xinhenghui Electronics was established as a joint-stock company through a restructuring process in November 2020 and has been operating for over three years [6]. Group 3: Substantive Conditions for IPO - The IPO has received the necessary approval from the CSRC, meeting the requirements set forth in the Securities Law and the ChiNext Listing Rules [6][9]. - The company's total share capital before the IPO was RMB 179.666 million, which increased to RMB 239.555467 million post-IPO, exceeding the minimum requirement of RMB 30 million [7]. - The company issued 59.888867 million shares in the IPO, representing over 25% of the total shares post-IPO [7]. - The company reported net profits for the years 2023 and 2024, meeting the requirement of positive net profits for the last two years and a cumulative net profit of no less than RMB 50 million [8]. - The company's directors, supervisors, and senior management have made commitments regarding the accuracy and completeness of the IPO application documents [8]. Group 4: Sponsorship and Commitments - The company has appointed Founder Securities as the sponsor for the IPO, which is registered with the CSRC and has membership with the Shenzhen Stock Exchange [9]. - The company and its major stakeholders have made public commitments regarding the IPO, including measures for accountability in case of non-compliance [9].
新恒汇(301678) - 首次公开发行股票并在创业板上市之上市公告书
2025-06-18 13:02
股票简称:新恒汇 股票代码:301678 新恒汇电子股份有限公司 (北京市朝阳区朝阳门南大街10号兆泰国际中心A座15层) 二〇二五年六月 (山东省淄博市高新区中润大道 187 号) 首次公开发行股票并在创业板上市 之 上市公告书 保荐人(主承销商) | 第一节 重要声明与提示 4 | | --- | | 一、重要声明 4 | | 二、创业板新股上市初期投资风险特别提示 4 | | 三、特别风险提示 7 | | 第二节 股票上市情况 11 | | 一、股票注册及上市审核情况 11 | | 二、股票上市的相关信息 11 | | 三、公司申请首次公开发行并上市时选择的具体上市标准及公开发行后 | | 达到所选定的上市标准及其说明 14 | | 第三节 发行人、实际控制人及股东持股情况 16 | | 一、发行人基本情况 16 | | 二、公司董事、监事、高级管理人员及其持有公司股票、债券的情况16 | | 三、控股股东及实际控制人的情况 18 | | 四、本次公开发行前已制定或实施的股权激励计划及员工持股计划..19 | | 五、本次发行前后的股本结构变动情况 42 | | 六、本次发行后公司前十名股东持股情况 4 ...
新恒汇(301678) - 首次公开发行股票并在创业板上市之上市公告书提示性公告
2025-06-18 13:02
本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 经深圳证券交易所审核同意,新恒汇电子股份有限公司(以下简称"本公司") 发行的人民币普通股股票将于2025年6月20日在深圳证券交易所创业板上市,上 市公告书全文和首次公开发行股票并在创业板上市的招股说明书全文披露于中 国 证 券 监 督 管 理 委 员 会 指 定 的 信 息 披 露 网 站 : 巨 潮 资 讯 网 , 网 址 www.cninfo.com.cn ;中证网,网址 www.cs.com.cn ;中国证券网,网址 www.cnstock.com ; 证券 时 报 网, 网 址 www.stcn.com ; 证 券 日报 网 , 网 址 www.zqrb.cn,供投资者查阅。 所属网页二维码:巨潮资讯网 一、上市概况 新恒汇电子股份有限公司 首次公开发行股票并在创业板上市 之上市公告书提示性公告 保荐人(主承销商):方正证券承销保荐有限责任公司 (一)股票简称:新恒汇 (四)首次公开发行股票数量:59,888,867股,占发行后公司总股本的比例 为25.00%,本次公开发行全部为新股,无老股转让。 二 ...